An inspiring and timely review by Paolo Gresele, published in Bleeding, Thrombosis and Vascular Biology, at the end of last year, fascinated me through the description of applications of artificial intelligence in the field of hemostasis and thrombosis, examining its advantages, drawbacks and future perspectives [...]
去年年底，《出血、血栓与血管生物学》（Bleeding, Thrombosis and Vascular Biology）杂志发表了保罗-格雷塞勒（Paolo Gresele）的一篇鼓舞人心且及时的评论文章，通过描述人工智能在止血和血栓领域的应用，审视其优点、缺点和未来前景，深深吸引了我 [...] 。
{"title":"Artificial intelligence, platelets and aspirin","authors":"Giovanni De Gaetano","doi":"10.4081/btvb.2024.130","DOIUrl":"https://doi.org/10.4081/btvb.2024.130","url":null,"abstract":"An inspiring and timely review by Paolo Gresele, published in Bleeding, Thrombosis and Vascular Biology, at the end of last year, fascinated me through the description of applications of artificial intelligence in the field of hemostasis and thrombosis, examining its advantages, drawbacks and future perspectives [...]","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":" 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140391710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This historical and personal review mainly focuses on the contribution of our research group and other Italian Colleagues to the development of aspirin pharmacology and its clinical use as an antithrombotic drug, in the Sixties, Seventies and Eighties. The main lines of research that have been developed over the last three decades, both at the experimental and clinical level, are not the subject of the present review.
{"title":"Blood platelets, prostaglandins and aspirin: a historical and personal rereading","authors":"Giovanni De Gaetano, C. Cerletti","doi":"10.4081/btvb.2024.121","DOIUrl":"https://doi.org/10.4081/btvb.2024.121","url":null,"abstract":"This historical and personal review mainly focuses on the contribution of our research group and other Italian Colleagues to the development of aspirin pharmacology and its clinical use as an antithrombotic drug, in the Sixties, Seventies and Eighties. The main lines of research that have been developed over the last three decades, both at the experimental and clinical level, are not the subject of the present review.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140284094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer is a leading cause of morbidity and mortality worldwide. It is also one of the strongest risk factors for venous thromboembolism (VTE), reported in approximately 20% of all cases of VTE diagnosed. The thrombotic effect of cancer and its treatments, however, is highly variable among patients and changes over the course of their cancer. Anticoagulant therapy remains the cornerstone of VTE treatment, but it is associated with a substantial rate of VTE recurrence and the potential for serious bleeding. The risk of bleeding in patients with cancer is also dependent on the cancer type and its treatments, often revealing underlying tumor invasion of mucosal or parenchymal tissues, and treatment complications such as thrombocytopenia or coagulopathy. Over the past few decades, efforts to improve the efficacy and safety of anticoagulant therapy for the treatment and prevention of cancer-associated thromboembolism have resulted in changes in the standard of practice. This evolution has been made possible largely through the development of new anticoagulants. This review will reflect on the major advances in the treatment of cancer-associated thrombosis and offer insights on how to address unmet needs in this field.
{"title":"Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape","authors":"Agnes Y.Y. Lee","doi":"10.4081/btvb.2024.111","DOIUrl":"https://doi.org/10.4081/btvb.2024.111","url":null,"abstract":"Cancer is a leading cause of morbidity and mortality worldwide. It is also one of the strongest risk factors for venous thromboembolism (VTE), reported in approximately 20% of all cases of VTE diagnosed. The thrombotic effect of cancer and its treatments, however, is highly variable among patients and changes over the course of their cancer. Anticoagulant therapy remains the cornerstone of VTE treatment, but it is associated with a substantial rate of VTE recurrence and the potential for serious bleeding. The risk of bleeding in patients with cancer is also dependent on the cancer type and its treatments, often revealing underlying tumor invasion of mucosal or parenchymal tissues, and treatment complications such as thrombocytopenia or coagulopathy. Over the past few decades, efforts to improve the efficacy and safety of anticoagulant therapy for the treatment and prevention of cancer-associated thromboembolism have resulted in changes in the standard of practice. This evolution has been made possible largely through the development of new anticoagulants. This review will reflect on the major advances in the treatment of cancer-associated thrombosis and offer insights on how to address unmet needs in this field.","PeriodicalId":517891,"journal":{"name":"Bleeding, Thrombosis and Vascular Biology","volume":"8 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140412974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：